Values are mean + SEM. (n=5 per group). aP<0.0001 significantly different from the diabetic group and abP<0.05 significantly different from the diabetic group treated with levcromakalim . D: diabetic group LevD : potassium channel activated diabetic group LevDG : potassium channel activated diabetic group treated with glibenclamide LevDM: potassium channel activated diabetic group treated with metformin LevDI20/40 : potassium channel activated diabetic group treated with insulin

Figure 4: The effect of levcromakalim treatment on the urine output of streptozotocin- induced diabetic rats treated with glibenclamide, metformin and insulin.